Effectiveness of perampanel as the only adjunctive anti‐seizure medication in adults: Final results from the observational PERPRISE study in Germany

Ähnliche Einträge

• PERPRISE: A prospective non‐interventional study of PERampanel as only adjunctive treatment in patients with PRImary or SEcondarily generalized tonic–clonic seizures: First interim analysis
  von: Bernhard J Steinhoff, et al.
  Veröffentlicht: (2024)
• Efficacy and safety of perampanel as first adjunctive therapy in patients with focal‐onset seizures or generalized tonic‐clonic seizures in four post‐marketing studies across regions
  von: Stefano Meletti, et al.
  Veröffentlicht: (2025)
• The cenobamate KORK study—A prospective monocenter observational study investigating cenobamate as an adjunctive therapy in refractory epilepsy, with comparisons to historical cohorts treated with add‐on lacosamide, perampanel, and brivaracetam
  von: Bernhard J. Steinhoff, et al.
  Veröffentlicht: (2024)
• Real‐world use of adjunctive perampanel for focal‐onset seizures in Italy: A mirroring clinical practice study of perampanel in adults and adolescents ( AMPA )
  von: Alfredo D'Aniello, et al.
  Veröffentlicht: (2025)
• Clinical efficacy and safety of perampanel monotherapy as primary anti‐seizure medication in the treatment of pediatric epilepsy: A single‐center, prospective, observational study
  von: Yanxia Gu, et al.
  Veröffentlicht: (2024)